Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Finished Goods (2016 - 2026)

Heron Therapeutics filings provide 11 years of Finished Goods readings, the most recent being $10.4 million for Q1 2026.

  • On a quarterly basis, Finished Goods rose 22.29% to $10.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.4 million, a 22.29% increase, with the full-year FY2025 number at $6.9 million, up 10.36% from a year prior.
  • Finished Goods hit $10.4 million in Q1 2026 for Heron Therapeutics, up from $6.9 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $22.0 million in Q3 2022 to a low of $6.2 million in Q4 2024.
  • Median Finished Goods over the past 5 years was $10.4 million (2026), compared with a mean of $12.3 million.
  • Biggest five-year swings in Finished Goods: soared 199.22% in 2022 and later crashed 58.01% in 2024.
  • Heron Therapeutics' Finished Goods stood at $18.7 million in 2022, then plummeted by 47.0% to $9.9 million in 2023, then tumbled by 37.11% to $6.2 million in 2024, then increased by 10.36% to $6.9 million in 2025, then surged by 50.5% to $10.4 million in 2026.
  • The last three reported values for Finished Goods were $10.4 million (Q1 2026), $6.9 million (Q4 2025), and $10.9 million (Q3 2025) per Business Quant data.